Small molecule glutaminase inhibitors block glutamate release from stimulated microglia

Ajit G. Thomas, Cliona M. O'Driscoll, Joseph Bressler, Walter Kaufmann, Camilo J. Rojas, Barbara S. Slusher

Research output: Contribution to journalArticle

Abstract

Glutaminase plays a critical role in the generation of glutamate, a key excitatory neurotransmitter in the CNS. Excess glutamate release from activated macrophages and microglia correlates with upregulated glutaminase suggesting a pathogenic role for glutaminase. Both glutaminase siRNA and small molecule inhibitors have been shown to decrease excess glutamate and provide neuroprotection in multiple models of disease, including HIV-associated dementia (HAD), multiple sclerosis and ischemia. Consequently, inhibition of glutaminase could be of interest for treatment of these diseases. Bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) and 6-diazo-5-oxo- l-norleucine (DON), two most commonly used glutaminase inhibitors, are either poorly soluble or non-specific. Recently, several new BPTES analogs with improved physicochemical properties were reported. To evaluate these new inhibitors, we established a cell-based microglial activation assay measuring glutamate release. Microglia-mediated glutamate levels were significantly augmented by tumor necrosis factor (TNF)-α, phorbol 12-myristate 13-acetate (PMA) and Toll-like receptor (TLR) ligands coincident with increased glutaminase activity. While several potent glutaminase inhibitors abrogated the increase in glutamate, a structurally related analog devoid of glutaminase activity was unable to block the increase. In the absence of glutamine, glutamate levels were significantly attenuated. These data suggest that the in vitro microglia assay may be a useful tool in developing glutaminase inhibitors of therapeutic interest.

Original languageEnglish (US)
Pages (from-to)32-36
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume443
Issue number1
DOIs
StatePublished - Jan 3 2014

Fingerprint

Glutaminase
Microglia
Glutamic Acid
Supravalvular Aortic Stenosis
Beryllium
Molecules
Diazooxonorleucine
AIDS Dementia Complex
Toll-Like Receptors
Myristic Acid
Sulfides
Glutamine
Small Interfering RNA
Multiple Sclerosis
Neurotransmitter Agents
Acetates
Ischemia
Tumor Necrosis Factor-alpha
Macrophages
Ligands

Keywords

  • Glutamate
  • Glutaminase
  • Glutamine
  • HIV-associated dementia (HAD)
  • Inflammation
  • Microglia

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Small molecule glutaminase inhibitors block glutamate release from stimulated microglia. / Thomas, Ajit G.; O'Driscoll, Cliona M.; Bressler, Joseph; Kaufmann, Walter; Rojas, Camilo J.; Slusher, Barbara S.

In: Biochemical and Biophysical Research Communications, Vol. 443, No. 1, 03.01.2014, p. 32-36.

Research output: Contribution to journalArticle

Thomas, Ajit G.; O'Driscoll, Cliona M.; Bressler, Joseph; Kaufmann, Walter; Rojas, Camilo J.; Slusher, Barbara S. / Small molecule glutaminase inhibitors block glutamate release from stimulated microglia.

In: Biochemical and Biophysical Research Communications, Vol. 443, No. 1, 03.01.2014, p. 32-36.

Research output: Contribution to journalArticle

@article{e8722293a0c643568b9c70c3931faa72,
title = "Small molecule glutaminase inhibitors block glutamate release from stimulated microglia",
abstract = "Glutaminase plays a critical role in the generation of glutamate, a key excitatory neurotransmitter in the CNS. Excess glutamate release from activated macrophages and microglia correlates with upregulated glutaminase suggesting a pathogenic role for glutaminase. Both glutaminase siRNA and small molecule inhibitors have been shown to decrease excess glutamate and provide neuroprotection in multiple models of disease, including HIV-associated dementia (HAD), multiple sclerosis and ischemia. Consequently, inhibition of glutaminase could be of interest for treatment of these diseases. Bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) and 6-diazo-5-oxo- l-norleucine (DON), two most commonly used glutaminase inhibitors, are either poorly soluble or non-specific. Recently, several new BPTES analogs with improved physicochemical properties were reported. To evaluate these new inhibitors, we established a cell-based microglial activation assay measuring glutamate release. Microglia-mediated glutamate levels were significantly augmented by tumor necrosis factor (TNF)-α, phorbol 12-myristate 13-acetate (PMA) and Toll-like receptor (TLR) ligands coincident with increased glutaminase activity. While several potent glutaminase inhibitors abrogated the increase in glutamate, a structurally related analog devoid of glutaminase activity was unable to block the increase. In the absence of glutamine, glutamate levels were significantly attenuated. These data suggest that the in vitro microglia assay may be a useful tool in developing glutaminase inhibitors of therapeutic interest.",
keywords = "Glutamate, Glutaminase, Glutamine, HIV-associated dementia (HAD), Inflammation, Microglia",
author = "Thomas, {Ajit G.} and O'Driscoll, {Cliona M.} and Joseph Bressler and Walter Kaufmann and Rojas, {Camilo J.} and Slusher, {Barbara S.}",
year = "2014",
month = "1",
doi = "10.1016/j.bbrc.2013.11.043",
volume = "443",
pages = "32--36",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Small molecule glutaminase inhibitors block glutamate release from stimulated microglia

AU - Thomas,Ajit G.

AU - O'Driscoll,Cliona M.

AU - Bressler,Joseph

AU - Kaufmann,Walter

AU - Rojas,Camilo J.

AU - Slusher,Barbara S.

PY - 2014/1/3

Y1 - 2014/1/3

N2 - Glutaminase plays a critical role in the generation of glutamate, a key excitatory neurotransmitter in the CNS. Excess glutamate release from activated macrophages and microglia correlates with upregulated glutaminase suggesting a pathogenic role for glutaminase. Both glutaminase siRNA and small molecule inhibitors have been shown to decrease excess glutamate and provide neuroprotection in multiple models of disease, including HIV-associated dementia (HAD), multiple sclerosis and ischemia. Consequently, inhibition of glutaminase could be of interest for treatment of these diseases. Bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) and 6-diazo-5-oxo- l-norleucine (DON), two most commonly used glutaminase inhibitors, are either poorly soluble or non-specific. Recently, several new BPTES analogs with improved physicochemical properties were reported. To evaluate these new inhibitors, we established a cell-based microglial activation assay measuring glutamate release. Microglia-mediated glutamate levels were significantly augmented by tumor necrosis factor (TNF)-α, phorbol 12-myristate 13-acetate (PMA) and Toll-like receptor (TLR) ligands coincident with increased glutaminase activity. While several potent glutaminase inhibitors abrogated the increase in glutamate, a structurally related analog devoid of glutaminase activity was unable to block the increase. In the absence of glutamine, glutamate levels were significantly attenuated. These data suggest that the in vitro microglia assay may be a useful tool in developing glutaminase inhibitors of therapeutic interest.

AB - Glutaminase plays a critical role in the generation of glutamate, a key excitatory neurotransmitter in the CNS. Excess glutamate release from activated macrophages and microglia correlates with upregulated glutaminase suggesting a pathogenic role for glutaminase. Both glutaminase siRNA and small molecule inhibitors have been shown to decrease excess glutamate and provide neuroprotection in multiple models of disease, including HIV-associated dementia (HAD), multiple sclerosis and ischemia. Consequently, inhibition of glutaminase could be of interest for treatment of these diseases. Bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) and 6-diazo-5-oxo- l-norleucine (DON), two most commonly used glutaminase inhibitors, are either poorly soluble or non-specific. Recently, several new BPTES analogs with improved physicochemical properties were reported. To evaluate these new inhibitors, we established a cell-based microglial activation assay measuring glutamate release. Microglia-mediated glutamate levels were significantly augmented by tumor necrosis factor (TNF)-α, phorbol 12-myristate 13-acetate (PMA) and Toll-like receptor (TLR) ligands coincident with increased glutaminase activity. While several potent glutaminase inhibitors abrogated the increase in glutamate, a structurally related analog devoid of glutaminase activity was unable to block the increase. In the absence of glutamine, glutamate levels were significantly attenuated. These data suggest that the in vitro microglia assay may be a useful tool in developing glutaminase inhibitors of therapeutic interest.

KW - Glutamate

KW - Glutaminase

KW - Glutamine

KW - HIV-associated dementia (HAD)

KW - Inflammation

KW - Microglia

UR - http://www.scopus.com/inward/record.url?scp=84890857120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890857120&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2013.11.043

DO - 10.1016/j.bbrc.2013.11.043

M3 - Article

VL - 443

SP - 32

EP - 36

JO - Biochemical and Biophysical Research Communications

T2 - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -